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Angioedema related to a deficiency in the C1-inhibitor protein is characterized by its lack of response to therapies including
antihistamine, steroids, and epinephrine. In the case of laryngeal edema, mortality rate is approximately 30 percent. The first case
of the acquired form of angioedema related to a deficiency in C1-inhibitor was published in 1972. In our paper, we present a case of
an acquired form of angioedema of the oropharyngeal region secondary to the simultaneous occurrence of two causative factors:
neutralization of C1-inhibitor by an autoantibody and the use of an angiotensin convertin enzyme inhibitor.
1. Introduction
Angioedema results from a loss of vascular integrity that
allows fluid to escape into soft tissues. Exposure of the vas-
culature to inflammatory mediators causes dilatation and
increased permeability of capillaries and venules.
The known causes of angioedema can be subdivided into
three groups depending upon the underlying mechanism:
mast cell mediated, bradykinine mediated, and unknown
etiology.
The angioedema related to a deficiency in protein C1-
inhibitor has bradykinine as a mediator. This deficiency can
be hereditary or acquired. Edema is characterized by its lack
of response to therapies including antihistamine, steroids,
and epinephrine [1]. We present a case of angioedema of the
head and neck related to an acquired deficiency in the protein
C1-inhibitor.
2. Case Report
A 53-year-old man presented to the emergency department
with a severe edema of the lower lip and tongue (Figure 1).
The edema developed suddenly without any obvious history
of trauma or foreign body ingestion. The clinical investiga-
tion did not show any history of allergic disorders. There
was no obvious history of edema. The patient was in good
health and was only known for arterial hypertension treated
by an angiotensin converting enzyme inhibitor. He had been
using this single medication for a few months. He did
not have any dyspnea and suﬀered only from swallowing
diﬃculties associated with modification of the voice. The
clinical examination did not show any other systemic disease,
or any edema at the level of the larynx.
A classic treatment of antihistamines, epinephrine, and
steroids, 250mg bid by intravenous administration was
introduced. No clinical response was noted nor any decrease
in the size of the edema. Progressively, respiratory distress
related to the extension of the edema to the tongue base
became conspicuous.
A dose of 25U/kg of C1-INH concentrate was then given
intravenously.
The edema disappeared completely within 35 minutes
after administration of the CI-INH concentrate (Figure 2).
The patient was followed up and no recurrence of the
edema was noted.
The biologic findings showed a level of C3 at 1.01 g/L
(normal levels: 0.75–1.40 g/L), and of C4 at 0.31 (normal
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0.15–0.35 g/L). The weight continent of C1-INH was at
0.30 g/mL (normal between 0.21–0.39 g/L), and the func-
tional level was at 61 ± 10% (normal between 70–130%).
We noted that the level of the anti-C1-INH autoantibod-
ies was positive and elevated to more than 23U/mL (normal
value ≤ 20U/mL).
3. Discussion
The C1-inhibitor (C1-INH) is an acute-phase reactant pro-
tein and is the primary inhibitor of the classical complement
pathway as well as of the coagulation (contact system),
fibrinolytic, and kinin-generation pathways [2, 3].
C1-INH inhibits the following plasma components of
these pathways:
(i) Hageman factor (factor XII),
(ii) clotting factor XI and XIIa,
(iii) plasma kallik.
Hereditary angioedema (HAE) is a rare autosomal dom-
inant genetic disorder resulting from an inherited deficiency
or dysfunction of the C1-INH. The prevalence of HAE is
estimated at 1 individual per 50,000, with reported ranges of
1 : 10,000 to 1 : 150,000 [4, 5]. There are no known diﬀerences
in prevalence among ethnic groups [6]. Men and women are
aﬀected equally. Two subtypes of HAE have been defined.
Type I HAE accounts for 85% of the cases and is
characterized by low levels of functional C1-INH. The levels
can occasionally drop to 30–50% of normal values in most
patients [7, 8].
Type II HAE results from the presence of a dysfunctional
C1-INH, which is present in normal or elevated amounts [8].
The gene for C1-INH maps to the long arm of chromo-
some 11. More than 100 mutations have been reported in
unrelated patients with HAE types I and II [9].
Patients with hereditary angioedema typically present
in late childhood or early adolescence with angioedema
following trauma, infection, dental procedures, or emotional
stress, with an increasing frequency and severity of episodes
with puberty, menses, and ovulation. These patients are
otherwise healthy.
Acquired angioedema (AAE) is most common in older
patients (>50 years), and most patients have associated
concomitant diseases. It can be divided into three subtypes.
(a) Type I is due to an excessive consumption of C1-INH
induced by hyperactivation of the classic complement
pathways with immune circulate complexes (lym-
phoproliferative syndrome, autoimmune diseases).
(b) Type II is due to a neutralization of C1-INH by
autoantibodies.
(c) Type III is due to angiotensin converting enzyme
inhibitors (ACE inhibitors). The angioedema occurs
in 0.1% to 0.7% of patients treated with this medica-
tion [10, 11]. The ACE inhibitors account for 20% to
30% of all angioedema cases presenting to emergency
departments.
The attacks of the angioedema most often aﬀect three
anatomical locations: the skin (cutaneous attack), gastroin-
testinal tract (gastrointestinal attacks), and upper airway
(laryngeal/pharyngeal attacks).
Symptoms with both forms of C1-INH deficiency can
range in severity from a minor inconvenience to a life-
threatening laryngeal edema by fatal asphyxiation with a
mortality rate of approximately 30% [12, 13]. Laryngeal
edema occurs in approximately one-half of all patients over
their lifetime, although only a few experience recurrent
episodes.
Laryngeal attacks account for less than 1% of all
angioedema episodes, and they are less common in patients
over age of 45 years [14]. The laryngeal swelling usually
develops over hours, with a reported mean of 7 hours.
Gastrointestinal attacks are experienced by a majority of
patients with hereditary angioedema and present as varying
degrees of gastrointestinal colic, nausea, vomiting, and/or
diarrhea, which result from bowel wall edema. Because of
the clinical similarities between bowel attacks of angioedema
and true surgical emergencies, as many as one-third of
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the patients with undiagnosed hereditary angioedema may
undergo unwarranted abdominal surgery [15].
The impact of hormonal fluctuations (including preg-
nancy) in women with hereditary angioedema is variable
[16, 17].
The mechanism of angioedema induced by angiotensin
converting enzyme inhibitors (ACE inhibitors) is a class
eﬀect that is directly related to the mechanism of action.
Thus, the ACE inhibitors have the eﬀect of decreasing
angiotensin II and increasing bradykinin production. One
report described a patient with ACE inhibitor-induced
angioedema whose bradykinin levels rose acutely during the
episode and normalized after it [11].
The C1-INH deficiency-induced angioedema is distin-
guished by its lack of response to therapies for other
types of angioedema, including antihistamines, steroids, and
epinephrine.
The eﬀective therapy is to replace the inhibitor (admin-
istration of C1-INH concentrate or fresh frozen plasma)
in case of severe edema, especially of the respiratory tract.
Increasing the hepatic synthesis of C1-INH, the anti-
fibrinolytic agents, or blocking bradykinin formation or
its receptor engagement should be attempted in cases of
moderate or recurrent episodes.
Prior to the introduction of eﬀective therapies for HAE,
up to one-third of patients died of asphyxiation [17].
However, despite eﬀective therapies, deaths secondary to
laryngeal attacks still occur with some regularity, although
data are limited. A series of Austrian, Swiss, and German
patients published in 2004 cited a mortality rate as high as
13% [1].
In our patient, the mechanism of edema formation was
related to two factors: the use of an ACE inhibitor and
the neutralization of C1-INH by an autoantibody anti-C1-
INH. This result is compatible with an acquired form of
angioedema related to a deficiency in C1-INH (the first case
was published in 1972). Only 50 cases of the acquired form of
angioedema have been published in the literature. Our case is
the first in which the two causative factors could be identified
in the same patient.
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